Among the criticisms the US Food and Drug Administration is facing following its approval of the Biogen, Inc./Eisai Co., Ltd. Alzheimer’s disease drug Aduhelm (aducanumab) is that the decision ran counter to the recommendations of the advisory committee the agency convened to review the product.
Three members of the Peripheral and Central Nervous System Drugs Advisory Committee have now resigned, expressing frustration at not being consulted on the accelerated approval and the agency’s disregard of the committee’s virtually unanimous rejection of the drug
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?